U.S. Markets close in 4 hrs 28 mins

Otezla: Shoring Up Celgene’s Top Line

Kenneth Smith
Otezla: Shoring Up Celgene’s Top Line

Celgene Corporation (CELG) is an integrated global biopharmaceutical company focused on innovative therapies for treating cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuroinflammation. Celgene’s Otezla is an oral small molecule inhibitor of PDE4. Otezla has been approved for the treatment of psoriatic arthritis and psoriasis in the United States, Japan, the European Union, and other international markets.